Dominantly Inherited Alzheimer Network (DIAN)

Description

The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.

Conditions

Alzheimer's Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.

Dominantly Inherited Alzheimer Network (DIAN)

Dominantly Inherited Alzheimer Network (DIAN)

Condition
Alzheimer's Disease
Intervention / Treatment

-

Contacts and Locations

Jacksonville

Mayo Clinic Jacksonville, Jacksonville, Florida, United States, 32224

Indianapolis

Indiana University-Indiana Alzheimer Disease Center, Indianapolis, Indiana, United States, 46202

Boston

Brigham and Women's Hospital, Boston, Massachusetts, United States, 02115

Saint Louis

Washington University in St. Louis School of Medicine, Saint Louis, Missouri, United States, 63108

New York

Columbia University, New York, New York, United States, 10032

Pittsburgh

University of Pittsburgh, Pittsburgh, Pennsylvania, United States, 15260

Providence

Butler Hospital, Providence, Rhode Island, United States, 02906

Seattle

University of Washington, Seattle, Washington, United States, 98195

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Written informed consent obtained from participant and collateral source prior to any study-related procedures.
  • * Aged 18 (inclusive) or older and the child of an affected individual (clinically or by testing) in a pedigree with a known mutation for ADAD.
  • * Cognitively normal to very mild or mild cognitive impairment (CDR score range 0-1.0). Primary enrollment will focus on the recruitment of asymptomatic adult children who are more than 15 years younger than the estimated age of symptom onset. Enrollment of new participants with moderate cognitive impairment is allowed with the prior approval of the DIAN Coordinating Center.
  • * Has two persons who are not their full-blooded siblings who can serve as collateral sources for the study.
  • * Fluent in a language approved by the DIAN Coordinating Center at about the 6th grade level (international equivalent) or above.
  • * Under age 18
  • * Medical or psychiatric illness that would interfere in completing initial and follow-up visits
  • * Requires nursing home level care
  • * Has no one who can serve as a study informant

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Washington University School of Medicine,

Randall J. Bateman, MD, PRINCIPAL_INVESTIGATOR, Washington University School of Medicine

Alisha Daniels, MD,MHA, STUDY_DIRECTOR, (314) 273-9057

Study Record Dates

2025-07